Preview or download our range of resources specifically designed for HCPs, highlighting the key benefits of REVOLADE for your ITP patients.
A piece about ITP treatment goals as well as REVOLADE’s platelet response, dose adjustment, mechanism of action and safety profile.
2019 INTERNATIONAL CONSENSUS REPORT (ICR) LEAFLET
Providing a summary of the updated recommendations, including therapy goals, strength of supporting data for treatment, personalising treatment plans and TPO-RAs for subsequent ITP therapy.
REVOLADE is indicated for the treatment of patients aged 1 year and above with primary ITP lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).1
REVOLADE is indicated in adult patients with chronic HCV infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.1
REVOLADE is indicated in adult patients with acquired SAA who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.1
Abbreviations: HCP, healthcare professional; HCV, hepatitis C virus; ICR, international consensus report; ITP, immune thrombocytopenia; SAA, severe aplastic anaemia; TPO-RA, thrombopoietin-receptor agonist.
- REVOLADE Summary of Product Characteristics.